124.47
-0.21 (-0.17%)
| Previous Close | 124.68 |
| Open | 123.31 |
| Volume | 899,910 |
| Avg. Volume (3M) | 841,985 |
| Market Cap | 6,016,465,920 |
| Price / Book | 69.69 |
| 52 Weeks Range | |
| Earnings Date | 14 May 2026 |
| Diluted EPS (TTM) | -3.05 |
| Total Debt/Equity (MRQ) | 113.89% |
| Current Ratio (MRQ) | 6.61 |
| Operating Cash Flow (TTM) | -102.25 M |
| Levered Free Cash Flow (TTM) | -62.83 M |
| Return on Assets (TTM) | -39.04% |
| Return on Equity (TTM) | -115.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Celcuity Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | -0.10 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.21% |
| % Held by Institutions | 81.78% |
| 52 Weeks Range | ||
| Median | 122.00 (-1.98%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 10 Mar 2026 | 122.00 (-1.98%) | Buy | 117.10 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |